Life Science News

Martin Olin, CFO and Deputy CEO, promoted to Chief Executive Officer

Sunstone Life Science Fund I portfolio company Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.

 

F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ralf Schmid to the position of Chief Financial Officer, effective from 4th July 2016. Ralf brings over 20 years’ experience to F2G, with considerable expertise in M&A, licensing, public and private market transactions.

Ralf Schmid joins F2G from Nabriva Theraputics AG (NASDAQ:NBRV), where he served on the management board since the company’s inception in 2006. In his role as Chief Financial and Chief Operating Officer, Ralf was instrumental in taking the company public on NASDAQ in September 2015. He has held various senior positions in finance and administration at several multi-national companies including Sandoz where he led the spin-off of Nabriva. Ralf holds a Master’s degree in finance and economics from Otto-Friedrich-Universität Bamberg, Germany.

 

Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today the treatment and successful operation of the first patient in a Phase I clinical trial. The study, sponsored by VAXIMM, will initially enroll six patients with operable recurrence of a glioblastoma (brain tumor) and is being conducted at the University Hospital in Heidelberg, Germany.

 

 

 Sunstone Life Science Fund II portfolio company Orphazyme has announced that the FDA has granted Fast Track designation for the investigation of arimoclomol intended for the treatment of Niemann-Pick disease type C. The FDA’s Fast Track Program is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. “The Fast Track designation is really good news for everyone involved in the AIDNPC trial, not least the sufferers of Niemann-Pick disease type C who deserve that every effort is made to expedite development of promising new therapies”, says Orphazyme ApS CEO Anders Hinsby

 

Sunstone Life Science Fund II portfolio company Orphazyme announced today that the first two patients have been dosed with arimoclomol in the Phase III ‘AIDNPC’ Niemann-Pick disease type C clinical trial programme.

The first two patients in the NPC-002 Interventional Study of the AIDNPC clinical programme were enrolled at the Rigshospitalet site in Copenhagen, Denmark, marking a key milestone in the development of a new treatment option for Niemann-Pick disease Type C (NP-C) patients.